
|Videos|January 3, 2018
Current and Emerging Immunotherapeutic Strategies in Melanoma
Author(s)Patrick Ott, MD, PhD
Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses current and emerging immunotherapeutic strategies in melanoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
5










































